QuickSwitch™ Custom Tetramer Kits

Fast, High-Quality Generation of New Tetramer Specificities

Rapid, high-quality creation of custom Class I and Class II MHC tetramers in your own lab is now a reality! Create new specificity tetramers in just a few hours with QuickSwitch™, a proprietary technology for exchanging peptides on an MHC tetramer.  With this kit, you will receive MHC allele with an irrelevant peptide bound.  The addition of a peptide exchange factor, and your peptide of interest, results in the creation of your custom MHC tetramer ready to use- all in one day.   The QuickSwitch™ Quant Tetramer Kit can quantify the exchange with the new peptide, thereby gathering binding affinity information for the MHC/peptide complex.  QuickSwitch™ can be used to generate custom MHC tetramers, or to screen numerous peptides.  This kit can be used for purposes such as epitope discovery, neoantigen vaccine research, verification of T cell staining using the new peptide specific tetramer, and more.

Functional screening of peptides for MHC class I binding is essential for vaccine design and immune monitoring.  The QuickSwitch™ assay kit allows discrimination of MHC binding from non-binding peptides.  This is particularly essential for the screening of immunogenic peptides from infectious agents or cancer neoantigens.  Tetramers resulting from peptide exchange with selected peptides can then be used for immune monitoring.  QuickSwitch™ kits are optimized for up to 10 peptide exchanges and multiple tests per resulting tetramer.

QuickSwitch™ Class I Custom Tetramer Kit

Peptide exchange, quantification, cell staining, and flow cytometry analysis can all be performed in one day!

Steps for custom Class I MHC Tetramer creation

High Throughput Immunogenic Peptide Discovery and Validation in 90 min.

  • Validate MHC binding peptides from in silico selected list of candidate peptides
  • Generate new specificity tetramers for immune monitoring
  • Perform functional stability studies for MHC binding peptides
  • Compare epitopes to rank better binders and perform epitope mapping

Class I Kits Available

Product DescriptionALLELEConjugates AvailableQuantification Included
QuickSwitch™ Quant HLA-A*02:01 Tetramer KitHLA-A*02:01PEAPCBV421Yes
QuickSwitch™ Quant HLA-A*03:01 Tetramer KitHLA-A*03:01PE, APC, BV421Yes
QuickSwitch™ Quant HLA-A*11:01 Tetramer KitHLA-A*11:01PEAPCBV421Yes
QuickSwitch™ Quant HLA-A*24:02 Tetramer KitHLA-A*24:02PE, APCBV421Yes
QuickSwitch™ Quant H-2 Kb Tetramer KitH-2KbPEAPCBV421Yes
QuickSwitch™ HLA-A*02:01 Peptide Screening KitHLA-A*02:01Yes

QuickSwitch™ Class II Custom Tetramer Kit

Class II Kits Available

Product DescriptionALLELEConjugates AvailableQuantification Included
QuickSwitch™ Quant HLA-DRB1*01:01 Tetramer KitHLA-DRB1*01:01PE, APC, BV421Yes
QuickSwitch™ Quant HLA-DRB1*04:01 Tetramer KitHLA-DRB1*04:01PE, APC, BV421Yes
QuickSwitch™ Quant HLA-DRB1*15:01 Tetramer KitHLA-DRB1*15:01PE, APC, BV421Yes

Additional QuickSwitch™ data

QuickSwitch™ HLA-A*02:01 tetramers detect similar percentages of low and high affinity CMV responses in PBMCs as classically folded tetramers

quickswitch grid

QuickSwitch™ Quant Kit can be used to assess peptide exchange so that you can select peptides with appropriate affinities to make functional tetramers prior to cell staining. In a study where HLA-A*02:01 QuickSwitch™ tetramer was incubated for 4 hours with two Mart-1 related peptides at a final of 20 μM in presence of peptide exchange factor #1, peptide exchange correlated with the theoretical peptide affinity of each peptide towards HLA-A*02:01.

QuickSwitch™ Quant Kit components:

  • Tetramer with an irrelevant exchangeable peptide in the MHC groove
  • A peptide exchange factor for catalyzing the peptide exchange reaction
  • A high affinity MHC-binding reference peptide used as peptide exchange positive control
  • FITC conjugated antibody specific of the exiting peptide
  • Magnetic beads conjugated with anti MHC antibody for tetramer capture
  • An Assay Buffer for diluting reagents and washing steps

H2-Kb Peptide-exchanged tetramers perform similarly to classically folded tetramers


H-2 Kb TRP2 used a negative control (#TB-5004-2; green), classically folded H-2 Kb OVA (#TB-5001-2; blue), and H-2 Kb QuickSwitch™ OVA (red) tetramer staining.

QuickSwitch™ HLA-A*24:02 tetramers perform similarly to classically folded tetramers


Data show CD3+ PBMCs stained with classically folded tetramers (A,E) or with QuickSwitch™ tetramers obtained by peptide exchange with the HLA-A*24:02 CMV peptide (B,C,D) or the HIV negative control peptide (F,G,H). 2 x 105 cells in 50 μL PBS-BSA-NaN3 buffer were stained for 30 min at RT with 1 μL of anti CD3-PC5.5 mAb (clone OKT3), 1 μL anti CD8-FITC (clone RPA-T8) (MBL) and 0.25 μg tetramer. Cells were fixed with a 0.5% formaldehyde PBS solution. Cells were analyzed on a Cytoflex S flow cytometer (Beckman Coulter). Cell doublets were discriminated using SSC-W/SSC-A gating.

Learn more about our Related Product Lines

Explore our video library of webinars

Download our free webinars which focus on different life science research topics and applications.  All webinars are presented by our scientists at MBL International.


  1. Morisaki T, Morisaki T, Kubo M, Onishi H, Hirano T, Morisaki S, Eto M, Monji K, Takeuchi A, Nakagawa S, Tanaka H, Koya N, Umebayashi M, Tsujimura K, Yew PY, Yoshimura S, Kiyotani K, Nakamura Y. Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis. Anticancer Res. 2021 Aug. Available at https://ar.iiarjournals.org/content/41/8/4101.abstract#sec1ps://ar.iiarjournals.org/content/41/8/4101.abstract#sec-1
  2. Sydney X. Lu, Emma de Neef, James D. Thomas, Luis Diaz, Jr., Omar Abdel-Wahab, Robert K. Bradley.  (2021) Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell, 12066.  Available at: /https://www.sciencedirect.com/science/article/abs/pii/S0092867421006905
  3. Hu, C., Shen, M., Han, X., Chen, Q., Li, L., Chen, S., . . . Jin, A. (2021). Identification of Cross-Reactive CD8 T Cell Receptors with High Functional Avidity to a SARS-CoV-2 Immunodominant Epitope and Its Natural Mutant Variants. Genes & Diseases. Available at: https://www.sciencedirect.com/science/article/pii/S2352304221000842
  4. Han, J., Yu, R., Duan, J., Li, J., Zhao, W., Feng, G., . . . Wang, J. (2021). Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non–small cell lung cancers. Science Advances, 7(21).  Available at: https://advances.sciencemag.org/content/7/21/eabd6971
  5. Teng Wei, Matthias Leisegang, Ming Xia, Kazuma Kiyotani, Ning Li, Chenquan Zeng, Chunyan Deng, Jinxing Jiang, Makiko Harada, Nishant Agrawal, Liangping Li, Hui Qi, Yusuke Nakamura & Lili Ren (2021) Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma, OncoImmunology, 10:1, Available at: https://www.tandfonline.com/doi/full/10.1080/2162402X.2021.1929726
  6. Poluektov, Y., Daftarian, P., & Delcommenne, M. C. (2020). Assessment of SARS-CoV-2 Specific CD4( ) and CD8 ( ) T Cell Responses Using MHC Class I and II Tetramers. Biorxiv Available at: https://www.biorxiv.org/content/10.1101/2020.07.08.194209v1://www.biorxiv.org/content/10.1101/2020.07.08.194209v1
  7. Son, E. T., Faridi, P., Paul-Heng, M., Leong, M., English, K., Ramarathinam, S. H., . . . Sharland, A. F. (2020). The self-peptide repertoire plays a critical role in transplant tolerance induction. Biorxiv. Available at: https://whttps://www.biorxiv.org/content/10.1101/2020.11.09.359968v2ww.biorxiv.org/content/10.1101/2020.11.09.359968v2
  8. Zhang, Y., Zhang, J., Chen, Y., Luo, B., Yuan, Y., Huang, F., . . . Zhang, H. (2020). The ORF8 Protein of SARS-CoV-2 Mediates Immune Evasion through Potently Downregulating MHC-I. Biorxiv. Available at: https://www.biorxiv.org/content/10.1101/2020.05.24.111823v1/www.biorxiv.org/content/10.1101/2020.05.24.111823v1
  9. Najafabadi, A. H., Zhang, J., Aikins, M. E., Abadi, Z. I., Liao, F., Qin, Y.,  Moon, J. J. (2020). Cancer Immunotherapy via Targeting Cancer Stem Cells Using Vaccine Nanodiscs. Nano Letters, 20(10), 7783-7792. Available at: https://pubs.acs.org/doi/10.1021/acs.nanolett.0c03414://pubs.acs.org/doi/10.1021/acs.nanolett.0c03414
  10. Song, X., Lu, Z., & Xu, J. (2020). Targeting cluster of differentiation 47 improves the efficacy of anti‑cytotoxic T‑lymphocyte associated protein 4 treatment via antigen presentation enhancement in pancreatic ductal adenocarcinoma. Experimental and Therapeutic Medicine. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444377/s://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444377/
  11. Lo, W., Parkhurst, M., Robbins, P. F., Tran, E., Lu, Y., Jia, L., . . . Rosenberg, S. A. (2019). Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer. Cancer Immunology Research, 7(4), 534-543 Available at: https://cancerimmunolres.aacrjournals.org/content/7/4/534
  12. Dustin, M. L., & Mayya, V. (2019). Faculty Opinions recommendation of T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. Available at: https://pubmed.ncbi.nlm.nih.gov/31398327/
  13. Smith, C. C., Chai, S., Washington, A. R., Lee, S. J., Landoni, E., Field, K., . . . Vincent, B. G. (2019). Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes. Cancer Immunology Research, 7(10), 1591-1604. Available at: https://cancerimmunolres.aacrjournals.org/content/7/10/1591.full-text.pdfps://cancerimmunolres.aacrjournals.org/content/7/10/1591.full-text.pdf
  14. Marc C Delcommenne, Olga Hrytsenko, Cynthia Tram, Genevieve Weir and Marianne M. Stanford. (2017) The QuickSwitch Quant HLA-A*02:01 Tetramer Kit can be used for determining the biological activity of a cancer vaccine. J Immunol, 198 (1 Supplement) 79.27 Available at: https://www.jimmunol.org/content/198/1_Supplement/79.27://www.jimmunol.org/content/198/1_Supplement/79.27